OKYO focuses on novel GPCR based therapeutics for eye diseases of high unmet need and non-opioid analgesics for chronic ocular pain, where large market potential exists. Specifically, OKYO is developing first-in-class drug candidates for the treatment of dry-eye, uveitis, acute and chronic ocular pain.
A novel class of membrane-anchored Chemerin receptor GPCR agonist that targets the inflammatory pathways to treat dry eye syndrome, uveitis and allergic conjunctivitis
An agonist for MAS-Related G Protein-Coupled Receptor (MRGPR), a non-opioid analgesic, for ocular and ocular pain management using novel topical and nasal formulations
OKYO Pharma is listed on the London Stock Exchange.